Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
AKT抑制剂MK-2206在伴有PIK3CA或AKT突变和/或PTEN缺失/PTEN突变的晚期乳腺癌患者中进行的II期临床试验
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-019-1154-8
Xing, Yan; Lin, Nancy U; Maurer, Matthew A; Chen, Huiqin; Mahvash, Armeen; Sahin, Aysegul; Akcakanat, Argun; Li, Yisheng; Abramson, Vandana; Litton, Jennifer; Chavez-MacGregor, Mariana; Valero, Vicente; Piha-Paul, Sarina A; Hong, David; Do, Kim-Anh; Tarco, Emily; Riall, Dianna; Eterovic, Agda Karina; Wulf, Gerburg M; Cantley, Lewis C; Mills, Gordon B; Doyle, L Austin; Winer, Eric; Hortobagyi, Gabriel N; Gonzalez-Angulo, Ana Maria; Meric-Bernstam, Funda